Cellares private stock trade

Cellares

Legal NameCellares Corporation
HeadquartersSouth San Francisco, CA
SectorBioTech

Cellares is a pioneering biotechnology company focused on advancing the field of cell therapy manufacturing through innovative solutions. With a mission to revolutionize the production of cell-based therapies, Cellares develops cutting-edge technologies and automation platforms that enable scalable and cost-effective manufacturing processes. By leveraging robotics, machine learning, and advanced data analytics, Cellares empowers biopharmaceutical companies to accelerate the development and commercialization of cell therapies, such as CAR-T and stem cell treatments. Founded on the principles of precision, efficiency, and scalability, Cellares is driving transformative change in the cell therapy industry, making these life-saving treatments more accessible and affordable for patients worldwide.

Learn more about Cellares IPO.

Secondary Pricing Information

$ .star in blue circleZX Index Value | Get Access
pricing graph placeholder
star in blue circleTo view Pre-IPO pricing data for and trade Cellares, contact us to request access.

Secondary Volume Information

$ .M star in blue circleAggregate Volume | Get Access
volume graph placeholder
star in blue circleTo view Pre-IPO volume data for and trade Cellares, contact us to request access.
View More

ZXData is a leading provider of real-time secondary data on private companies. ZXData's dataset incoroporates closed trades with 20bn+ in volume. In addition, it incorporates $200bn+ of buy/sell prices and $70bn+ of reported marks to provide private market investors, trading desks, lenders, and companies with unprecedented market intelligence on private companies.

Disclaimer

This report is provided for informational purposes only and does not constitute a recommendation or solicitation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. The values shown in this report are not indicative price quotations. This report does not constitute investment advice, nor does this report constitute a "research report" as defined by FINRA Rule 2241 or a "debt research report" as defined by FINRA Rule 2242.

The ZXData and the information contained in this report, some of which have been obtained from third-party sources, are provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. Neither Zanbato Inc. (“Zanbato”) nor its affiliates guarantee the accuracy or completeness of the data contained in this report, or its computation and compilation.

The ZXData and this report constitute Zanbato’s valuable intellectual property. You are expressly prohibited from copying, modifying, transmitting or redistributing the ZXData or this report without Zanbato’s prior written consent.